Nausea News and Research RSS Feed - Nausea News and Research

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.
FDA accepts Eisai's sNDA for perampanel for treatment of PGTC seizures

FDA accepts Eisai's sNDA for perampanel for treatment of PGTC seizures

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company's Supplemental New Drug Application (sNDA) for its in-house-discovered AMPA receptor antagonist perampanel for the treatment of primary generalized tonic-clonic (PGTC) seizures. [More]
Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen Research & Development, LLC today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) to the U.S. Food and Drug Administration by its strategic partner Pharmacyclics, Inc. [More]
Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved OFEV (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF). [More]
Most surgical patients lack knowledge about roles of physician anesthesiologists

Most surgical patients lack knowledge about roles of physician anesthesiologists

Most surgical patients know a physician anesthesiologist will "put them to sleep," but what they don't realize is that this medical doctor plays a major role in preparing them for the operation. Just as important, these physicians keep them safe and preserve their health during surgery and help them recover as quickly and as comfortably as possible, according to a study presented at the ANESTHESIOLOGY 2014 annual meeting. [More]
Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. [More]
Texas health worker contracts Ebola, fueling questions about training and preparedness

Texas health worker contracts Ebola, fueling questions about training and preparedness

The case, the first in which the disease was transmitted in the U.S., raises questions about whether regular hospitals around the country are ready to safely deal with the virus. [More]
Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

Astellas reported today that isavuconazole demonstrated successful outcomes in the treatment of mucormycosis according to data from the phase 3 isavuconazole VITAL study being presented at IDWeek on October 10, 2014, in Philadelphia, Pa. [More]
Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Colonoscopy is an important and widely used screening tool for colorectal cancer, but for many patients the bowel-preparation process is more uncomfortable than the procedure itself. To offer an alternative choice in bowel preparation, Ferring Pharmaceuticals Inc. will introduce a new cranberry flavor option of PREPOPIK in January 2015. [More]
Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated demonstrated a statistically significant reduction in the incidence of PONV with APD421 compared to placebo in adult surgical patients at moderate to high risk of suffering PONV (PONV is defined as any episode of emesis or use of antiemetic rescue medication in the first 24 hours after surgery). [More]
Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company, has announced the launch of its lead product Rasuvo (methotrexate) injection for patients with rheumatoid arthritis (RA), poly-articular-course juvenile idiopathic arthritis (pJIA) and psoriasis in the U.S. [More]
Researchers reveal that drug-food interactions may endanger mountaineer’s health

Researchers reveal that drug-food interactions may endanger mountaineer’s health

University of the Basque Country researchers have studied the nutritional and health situations existing at high altitudes as well as the routinely used nutritional ergogenic and pharmacological aids. According to their study, the possible interactions between drugs and food and nutrients taken may endanger the mountaineer’s health if all this is not conducted under strict control. [More]
New scaling law helps predict humans' risk of blast-induced traumatic brain injury

New scaling law helps predict humans' risk of blast-induced traumatic brain injury

Since the start of the military conflicts in Iraq and Afghanistan, more than 300,000 soldiers have returned to the United States with traumatic brain injury caused by exposure to bomb blasts - and in particular, exposure to improvised explosive devices, or IEDs. Symptoms of traumatic brain injury can range from the mild, such as lingering headaches and nausea, to more severe impairments in memory and cognition. [More]

Teva Canada recalls Biomedic Acetaminophen with Codeine owing to missing child-resistant packaging

Teva Canada Limited, in consultation with Health Canada, is recalling one lot (#669745) of Biomedic Acetaminophen with Codeine (30 caplets with 300 mg acetaminophen and 8 mg codeine) due to missing child-resistant packaging. [More]
Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC). [More]
Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain. [More]
Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

A new drug, anamorelin, improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain. [More]
Phase III trial: Rolapitant lessens chemotherapy-induced nausea and vomiting

Phase III trial: Rolapitant lessens chemotherapy-induced nausea and vomiting

Rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to the results of a phase III trial presented for the first time today at the ESMO 2014 Congress in Madrid, Spain. [More]
Understanding ways to treat, cure eosinophilic gastritis

Understanding ways to treat, cure eosinophilic gastritis

Investigators at Cincinnati Children's Hospital Medical Center have published the first study to extensively characterize eosinophilic gastritis (EG). [More]
Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Elusys Therapeutics, Inc., a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed three phase 3 healthy adult volunteer safety studies of obiltoxaximab (ETI-204). [More]
People who experience migraine in middle age may develop movement disorders later in life

People who experience migraine in middle age may develop movement disorders later in life

A new study suggests that people who experience migraine in middle age may be more likely to develop Parkinson's disease, or other movement disorders later in life. Those who have migraine with aura may be at double the risk of developing Parkinson's, according to the study published in the September 17, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]